Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-18 09:45 am Purchase |
2025-04-11 | 13G | Regal Rexnord Corporation RRX |
VIKING GLOBAL INVESTORS LP | 3,546,112 5.300% |
3,546,112 (New Position) |
Filing History |
| 2025-03-12 4:28 pm Unchanged |
2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% |
0 (Unchanged) |
Filing History |
| 2025-03-12 4:27 pm Unchanged |
2024-02-01 | 13D | Cazoo Group Ltd CZOOF |
VIKING GLOBAL INVESTORS LP | 2,142,728 43.800% |
0 (Unchanged) |
Filing History |
| 2025-02-14 4:58 pm Purchase |
2025-02-10 | 13G | Sionna Therapeutics, Inc. SION |
VIKING GLOBAL INVESTORS LP | 2,952,754 6.700% |
2,952,754 (New Position) |
Filing History |
| 2025-02-14 4:50 pm Sale |
2024-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
VIKING GLOBAL INVESTORS LP | 0 0.000% |
-1,752,656 (Position Closed) |
Filing History |
| 2025-02-14 4:50 pm Sale |
2024-12-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS |
VIKING GLOBAL INVESTORS LP | 6,978,534 6.500% |
-1,046,031 (-13.04%) |
Filing History |
| 2025-02-14 4:50 pm Sale |
2024-12-31 | 13G | APi Group Corporation APG |
VIKING GLOBAL INVESTORS LP | 21,537,518 7.800% |
-5,494,998 (-20.33%) |
Filing History |
| 2025-01-31 7:18 pm Sale |
2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% |
-3,065,616 (-12.20%) |
Filing History |
| 2024-11-14 4:32 pm Unchanged |
2024-09-30 | 13G | Tourmaline Bio, Inc. TRML |
VIKING GLOBAL INVESTORS LP | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-11-14 4:31 pm Purchase |
2024-09-30 | 13G | Ginkgo Bioworks Holdings, Inc. DNA |
VIKING GLOBAL INVESTORS LP | 3,577,128 8.300% |
3,577,128 (New Position) |
Filing History |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 1,481,146 1.600% |
-4,678,000 (-75.95%) |
Filing History |
| 2024-11-14 4:31 pm Unchanged |
2024-09-30 | 13G | PepGen Inc. PEPG |
VIKING GLOBAL INVESTORS LP | 1,482,434 4.500% |
0 (Unchanged) |
Filing History |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
VIKING GLOBAL INVESTORS LP | 0 0.000% |
-4,247,914 (Position Closed) |
Filing History |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | Roivant Sciences Ltd. ROIV |
VIKING GLOBAL INVESTORS LP | 54,099,066 7.300% |
-15,269,895 (-22.01%) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Viking Therapeutics, Inc. VKTX |
VIKING GLOBAL INVESTORS LP | 721,926 0.600% |
-4,423,186 (-85.97%) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Verastem, Inc. VSTM |
VIKING GLOBAL INVESTORS LP | 0 0.000% |
-2,531,829 (Position Closed) |
Filing History |
| 2024-11-06 5:04 pm Unchanged |
2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% |
0 (Unchanged) |
Filing History |
| 2024-11-06 5:03 pm Purchase |
2024-02-01 | 13D | Cazoo Group Ltd CZOOF |
VIKING GLOBAL INVESTORS LP | 2,142,728 43.800% |
2,121,301 (+9900.00%) |
Filing History |
| 2024-09-30 4:29 pm Purchase |
2024-09-20 | 13G | BioMarin Pharmaceutical Inc. BMRN |
VIKING GLOBAL INVESTORS LP | 9,753,293 5.100% |
9,753,293 (New Position) |
Filing History |
| 2024-08-20 8:42 pm Unchanged |
2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% |
0 (Unchanged) |
Filing History |